Evofem Biosciences, Inc.
Evofem Biosciences is a San Diego-based commercial-stage biopharmaceutical company focused on products for women’s sexual and reproductive health. Its U.S. commercial portfolio includes PHEXX, a prescription hormone-free vaginal contraceptive gel used before intercourse, and SOLOSEC, a single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis. The company promotes both products through its sales team to obstetrician/gynecologists and affiliated health professionals, and offers women access to PHEXX prescriptions through a telehealth platform. Evofem makes money by commercializing its products in the United States and licensing commercial rights in other markets. It has licensed PHEXX and SOLOSEC rights in the Middle East and North Africa to Pharma 1 Drug Store, which is responsible for regulatory approvals and commercial activities in the licensed countries.
No enriched coverage for $EVFM in the last 7 days.
No SEC Form 4 filings for $EVFM in the last 30 days.
See all $EVFM insider activity →Evofem Biosciences amended its convertible notes agreement with Adjuvant, extending maturity to Dec. 1, 2026, or earlier events. The amendment restricts prepayment and removes certain covenants. The changes aim to extend runway and increase flexibility. The agreement was signed and effective on Oct. 9, 2026, according to the company's SEC filing.
Evofem Biosciences, Inc. (EVFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Amendment to Securities Purchase Agreement On October 9, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (
Evofem Biosciences, Inc. (EVFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth Strategy — Additional manufacturing source expected to improve supply chain flexibility and reduce unit costs by 40% or more following regulatory approval — SAN DIEGO, CA, S
Recent EVFM coverage spans corporate actions and mergers & acquisitions.
The amendment extends debt maturity and adds prepayment restrictions, which may limit financing flexibility and could be viewed negatively by investors.
The amendment tightens timing around when the convertible notes can be due, potentially increasing refinancing or change-of-control risk for EVFM.
Adds incremental manufacturing capacity for PHEXX, with potential margin support contingent on FDA approval and an sNDA submission in mid-2027.
The filing discloses a new, short-dated financing obligation that increases near-term cash outflow risk and may pressure liquidity.
The transaction could provide liquidity/exit for certain noteholders, but EVFM’s own equity holders’ payoff depends on conversion mechanics and deal terms not provided.
AlphAI scores every news story that mentions EVFM with an AI model for sentiment and relevance, and aggregates insider trades from Evofem Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Evofem Biosciences amended its convertible notes agreement with Adjuvant, extending maturity to Dec. 1, 2026, or earlier events. The amendment restricts prepayment and removes certain covenants. The changes aim to extend runway and increase flexibility. The agreement was signed and effective on Oct. 9, 2026, according to the company's SEC filing.
1 min readEvofem Biosciences, Inc. (EVFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Amendment to Securities Purchase Agreement On October 9, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (
4 min readEvofem Biosciences, Inc. (EVFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth Strategy — Additional manufacturing source expected to improve supply chain flexibility and reduce unit costs by 40% or more following regulatory approval — SAN DIEGO, CA, S
4 min readEvofem Biosciences, Inc. (EVFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THIS NOTE MAY NOT BE OFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHER
2 min readHUB Cyber Security (Nasdaq: HUBC) said it acquired senior subordinated convertible notes and purchase rights of Evofem Biosciences (OTCMKTS: EVFM) using only HUB equity, at no cash cost. HUB cited a broader restructuring to cut costs, reduce headcount ~50%, and improve liquidity/governance. Evofem reported $20M+ sales in 2025.
4 min read
